Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Ovarian cancer is one of the most lethal gynaecological malignancies worldwide. Despite high success rates following first time treatment, this heterogenous disease is prone to recurrence. Oncogenic activity of receptor tyrosine kinases is believed to drive the progression of ovarian cancer. Here we...

Full description

Bibliographic Details
Main Authors: Aimee Rendell, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, Yu Yu
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
ovarian cancer
tyrosine kinases
platinum resistance
recurrent cancers
cancer vaccine
kinase inhibitors
Online Access:https://www.mdpi.com/2227-9059/10/9/2113

Internet

https://www.mdpi.com/2227-9059/10/9/2113

Similar Items